Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

U.S. Sales of Rival to Biogen’s Tecfidera Blocked for 13 Days(1)

Jan. 22, 2020, 4:11 PM

A judge has blocked U.S. sales of Banner’s new multiple-sclerosis drug Bafiertam for 13 days “to allow Biogen time to pursue an injunction pending appeal” of a ruling that the new drug doesn’t infringe a patent for its Tecfidera.

  • The order blocking Bafiertam sales, approved Wednesday in federal court in Wilmington, Delaware, will expire either on Feb. 4 at 10 a.m. or if the Court of Appeals for the Federal Circuit denies any request to block the drug’s sales pending appeal
  • Order doesn’t prohibit the U.S. Food and Drug Administration from granting Bafiertam final approval, nor does it bar ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.